ARTERIA business model consists of developing NCEs in the metabolic diseases area and find Pharmaceutical Partners for late stage development and commercialisation on lead compounds for which pharmacological evidence has been established at early preclinical stage, up to phase I or II.

ARTERIA is performing its development activities through different subcontracting partnerships. It allows the company to choose the best subcontractors on a case by case basis, optimizing costs, deadlines and quality.